PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
PolyPid Ltd. (Nasdaq: PYPD) announced it will release its first quarter 2022 financial results on May 11, 2022, before U.S. market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced it will release its first quarter 2022 financial results on May 11, 2022, before U.S. market opening.
A conference call and webcast will follow at 8:30 AM ET to discuss the results and operational highlights.
PolyPid focuses on improving surgical outcomes with its proprietary PLEX technology, currently advancing its lead product D-PLEX100 in Phase 3 trials for preventing surgical site infections.
Positive
- Lead product D-PLEX100 in Phase 3 trials for surgical site infection prevention.
- Focus on improving surgical outcomes with proprietary PLEX technology.
Negative
- None.
Details
News Market Reaction – PYPD
The recorded move for PYPD in the trading session of this news was +2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, May 11, 2022 |
| Time: | 8:30 AM Eastern Time |
| United States: | +1 877-870-9135 |
| Israel: | +972 1809 213-985 |
| International: | +44 (0) 2071 928338 |
| Conference ID: | 3450787 |
| Webcast: | https://edge.media-server.com/mmc/p/djs2mjt6 |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
Media:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.